WHO raises DRC Ebola outbreak risk assessment to very high  

The World Health Organisation has raised the national risk assessment of the Bundibugyo Ebola virus strain in the Democratic Republic of Congo to “very high”.

The classification adjustment follows a significant escalation in transmission velocity and casualty figures within the affected regions.

Cross-border transmission triggers updated regional threat matrix
Tedros Ghebreyesus, the WHO Director-General, stated that the epidemiological situation has deteriorated sufficiently to warrant an immediate reclassification of the threat level.

“We are now revising our risk assessment to very high at the national level, high at the regional level, and low at the global level,” Ghebreyesus confirmed.

In the DRC, public health authorities have confirmed 82 cases and seven deaths. However, field teams are currently tracking 177 suspected deaths and approximately 750 suspected cases. This significant statistical disparity strongly implies that the viral outbreak is far more widespread than official laboratory-confirmed metrics indicate.

The risk of broader regional contagion has already materialised. Neighbouring Uganda has recorded two imported cases linked to travellers crossing the Congolese border, one of whom has died.

High transmission velocity alters containment dynamics
Abdirahman Mahamud, the WHO Emergency Operations Director, warned that the specific structural characteristics of this strain enable rapid transmission, driving acute concern among international health officials.

“The potential of this virus spreading rapidly is high, very high, and that changed the whole dynamic,” Mahamud noted.

Clinical trials pivot to experimental antiviral interventions
Regarding potential therapeutic interventions, Sylvie Briand, the WHO Chief Scientist, suggested that an experimental antiviral drug, Obeldesivir, could be deployed as a prophylactic measure to protect individuals with known exposure to the virus.

The pharmaceutical compound, developed by Gilead Sciences, was originally designed to combat COVID-19 and remains under clinical evaluation for efficacy against Ebola strains. Briand emphasised that while the therapeutic data is promising, the drug must strictly be administered under rigorous medical oversight.